While the role of ethnicity deserves further investigation, there are no reasons to support the existence of confounding by indication or channeling bias (i.e., preferential prescription towards more severe patients with risk factors for ILD) and, if present, it should apply to all CDK4/6 inhibitors. This evidence concerns the gene CDK4 and interstitial lung disease.